相关临床试验
217
37 进行中
药物批准
16
批准总数
监管机构
2
监管机构数
成立时间
N/A
进行中（未招募）
36
16.6%
已完成
147
67.7%
尚未招募
1
0.5%
招募中
7
3.2%
终止
6
2.8%
- Mitsubishi Tanabe Pharma America will present four poster presentations on investigational ND0612 at the 2025 International Congress of Parkinson's Disease and Movement Disorders. - The presentations will share findings from the pivotal Phase 3 BouNDless study evaluating ND0612 versus standard of care in Parkinson's disease patients experiencing motor fluctuations. - ND0612 is a 24-hour continuous subcutaneous infusion of liquid levodopa/carbidopa designed to address motor fluctuations in Parkinson's disease patients. - Study data will cover pharmacokinetics, efficacy across disease stages, dyskinesia outcomes, and reduced falls with the investigational therapy.
- A retrospective analysis published in Muscle and Nerve demonstrates that RADICAVA ORS (edaravone) treatment is associated with improved survival outcomes and slower functional decline compared to historical placebo controls. - The study showed an 84% decreased risk of death and a mean survival prolongation of 7.3 months in ALS patients treated with RADICAVA ORS versus matched historical controls from the PRO-ACT database. - Over 48 weeks, patients receiving RADICAVA ORS experienced a significantly slower rate of decline in physical function as measured by ALSFRS-R scores compared to placebo patients. - The analysis included data from 78 propensity score-matched patients in the primary cohort and expanded to 210 patients in a broader post-hoc analysis to confirm the robustness of results.
- Comprehensive analysis of peripheral blood immune cell profiles in NMOSD patients reveals widespread alterations affecting neutrophils, B cells, T cells, and other immune populations beyond traditional B cell dysfunction. - B cell depletion therapy with inebilizumab (anti-CD19) and rituximab (anti-CD20) demonstrates differential effects on immune cell populations, with inebilizumab providing broader B cell elimination including antibody-producing plasma cells. - Study findings suggest NMOSD pathogenesis involves complex immune network disruptions, with B cell depletion therapy working through multiple mechanisms beyond AQP4 antibody reduction, including restoration of regulatory B cells and modulation of T cell interactions.
- Mitsubishi Tanabe Pharma America will present 11 studies at the American Academy of Neurology 2025 Annual Meeting, including research on investigational ND0612 for Parkinson's disease and RADICAVA formulations for ALS. - Key Parkinson's disease presentations will highlight Phase 3 BouNDless trial results showing the impact of 24-hour subcutaneous levodopa/carbidopa infusion on motor function and quality of life outcomes. - Multiple ALS studies will be presented, including final results from extension studies evaluating RADICAVA ORS safety and efficacy, plus real-world data on at-home telespirometry and treatment utilization patterns.
- GV20 Therapeutics has formed a strategic research collaboration with Mitsubishi Tanabe Pharma Corporation to develop first-in-class antibody-drug conjugates targeting novel tumor antigens. - The partnership will utilize GV20's proprietary STEAD AI platform for antibody discovery combined with MTPC's expertise in linker-payload technology to advance innovative cancer therapeutics. - Under the agreement, GV20 will receive an upfront payment plus milestone payments, while MTPC gains exclusive negotiation rights for licensing the antibodies during the collaboration period.
- Mitsubishi Tanabe Pharma America published new preclinical research demonstrating edaravone's ability to mitigate TDP-43 mislocalization, a hallmark feature in over 97% of sporadic ALS cases. - The study, using iPSC-derived motor neurons from an ALS patient, showed edaravone significantly reduced abnormal cytoplasmic accumulation of TDP-43 and restored its nuclear localization through the SIRT1-XBP1 pathway. - These findings suggest edaravone may offer broader therapeutic benefits in ALS beyond its known antioxidant properties, potentially addressing both oxidative stress and protein mislocalization mechanisms.
- A real-world data analysis by Mitsubishi Tanabe Pharma America suggests that edaravone is associated with longer disease progression milestone-free time in ALS patients. - The study, while observational and retrospective, offers insights into the potential benefits of edaravone in delaying key disease milestones. - RADICAVA IV and RADICAVA ORS are supported by data from clinical trials and real-world evidence studies evaluating efficacy and safety. - Edaravone, discovered and developed by Mitsubishi Tanabe Pharma Corporation, is available in both IV (RADICAVA) and oral (RADICAVA ORS) formulations for ALS treatment.
- Mitsubishi Tanabe Pharma America (MTPA) presented real-world data on RADICAVA ORS® (edaravone) at the 2024 NASP Annual Meeting, focusing on ALS treatment. - The presentations included patient demographics, treatment duration, progression milestones, and healthcare resource utilization among RADICAVA ORS®-treated individuals. - Analyses of clinical characteristics from Optum's Clinformatics® Data Mart (CDM) provided insights into the real-world impact of RADICAVA ORS® in ALS treatment. - These findings underscore MTPA's commitment to advancing medical knowledge and improving patient care in amyotrophic lateral sclerosis.
- ND0612, a continuous subcutaneous infusion of levodopa/carbidopa, significantly reduced motor symptom fluctuations in advanced Parkinson's disease over one year. - The BouNDless study and its extension, BeyoND, demonstrated a 2.02-hour reduction in daily off-time and a 2.11-hour increase in on-time without troublesome dyskinesia. - Patients treated with ND0612 experienced improvements in motor signs, daily living activities, and overall quality of life compared to oral levodopa/carbidopa. - The FDA is currently reviewing ND0612 for potential approval as a new treatment option for Parkinson's patients experiencing motor fluctuations.
